FDA approves Dizal’s Zegfrovy to treat adults with NSCLC
Zegfrovy is designed to target a broad range of EGFR mutations while maintaining selectivity over wild-type EGFR.
Therapy Area
Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention
Sanofi agrees to invest $25m in Adagene
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
Merck concludes SpringWorks acquisition for $3.4bn
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Oncternal sells assets for up to $68m and calls it quits
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
